cas 19064-64-3|| where to buy 3,6-dichloro-4-methylpyridazine

Nombre del producto:3,6-dichloro-4-methylpyridazine

IUPAC Name:3,6-dichloro-4-methylpyridazine

Unidad de embalaje	Stock disponible	Precio($)
CM102253-100g	in stock	Şƚ
CM102253-500g	in stock	ȅȖŞ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 19064-64-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :19064-64-3; Fórmula molecular:C5H4Cl2N2; Punto de fusión:-; Código de sonrisas:CC1=CC(Cl)=NN=C1Cl; Densidad:

: Número de catálogo:CM102253; Peso molecular:163; Punto de ebullición:272.1°C; Nº Mdl:MFCD00006465; Almacenamiento:Store at 2-8°C.

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.